Novartis sells parts of Sandoz US to India's Aurobindo for $900 million
Updated : September 06, 2018 10:07 AM IST
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.
The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance-based payments, Novartis said.
The 131-year-old Sandoz unit was hurt by price pressure in the United States, prompting Novartis Chief Executive Officer Vas Narasimhan to sell the Sandoz unit.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more